Symmetry Partners LLC Invests $291,000 in CVS Health Co. (NYSE:CVS)

Symmetry Partners LLC purchased a new stake in shares of CVS Health Co. (NYSE:CVS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,478 shares of the pharmacy operator's stock, valued at approximately $291,000.

Other large investors have also made changes to their positions in the company. TD Private Client Wealth LLC lifted its holdings in CVS Health by 28.7% in the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator's stock worth $2,951,000 after purchasing an additional 10,465 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of CVS Health by 4.8% during the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock valued at $90,200,000 after buying an additional 66,244 shares during the last quarter. Sompo Asset Management Co. Ltd. boosted its position in shares of CVS Health by 8.4% during the third quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator's stock worth $8,459,000 after acquiring an additional 10,453 shares during the last quarter. Hall Laurie J Trustee grew its stake in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock valued at $517,000 after acquiring an additional 11,468 shares in the last quarter. Finally, B&D White Capital Company LLC purchased a new stake in CVS Health in the 4th quarter worth $417,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Up 0.7 %

CVS stock traded up $0.49 during midday trading on Monday, reaching $67.54. The company's stock had a trading volume of 11,328,816 shares, compared to its average volume of 11,101,449. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $80.75. The firm has a market capitalization of $85.15 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 0.98 and a beta of 0.54. The stock has a fifty day simple moving average of $60.92 and a two-hundred day simple moving average of $57.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, equities research analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 3.94%. CVS Health's payout ratio is currently 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of research analyst reports. Edward Jones upgraded CVS Health from a "hold" rating to a "buy" rating in a research report on Thursday, January 30th. StockNews.com raised CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. TD Cowen raised their target price on shares of CVS Health from $73.00 to $80.00 and gave the company a "buy" rating in a report on Monday, November 25th. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. Finally, Leerink Partnrs raised shares of CVS Health from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $70.39.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is currently owned by corporate insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.